Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 16/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.47 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170727 | 1.00 | OPRM1 (0.64) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL20170724 | 0.96 | OPRM1 (0.62) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL20170770 | 0.82 | OPRM1 (0.42) | OPRM1OPRK1OPRD1 | |
| SCHEMBL20170848 | 0.82 | OPRM1 (0.42) | OPRM1OPRK1OPRD1 | |
| SCHEMBL20170822 | 0.76 | OPRM1 (0.51) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL20170759 | 0.75 | OPRM1 (0.52) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL14035025 | 0.74 | OPRM1 (0.53) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL13013415 | 0.74 | OPRM1 (0.53) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL20170774 | 0.73 | OPRM1 (0.70) | OPRM1OPRK1MRGPRX2MAPTOPRD1 | |
| SCHEMBL20170750 | 0.72 | OPRM1 (0.51) | OPRM1OPRK1MRGPRX2MAPTOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2453895-B1 | (+) - MORPHINANS AS ANTAGONISTS OF TOLL-LIKE RECEPTOR 9 AND THERAPEUTIC USES THEREOF | MALLINCKRODT LLC (US) | 2018-05-23 | — | — | EP | disclosed |